Skip to Main Content

Targeted cancer therapy developer Loxo Oncology (LOXO) is licensing its two lead drugs to the German pharma giant Bayer, the companies announced Tuesday.

Under the agreement, Loxo will receive $400 million upfront from Bayer in exchange for global development and marketing rights to larotrectinib and LOXO-195. Both drugs target a rare genetic flaw known as TRK gene fusion found across a range of different cancer types.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!